CompanyCORTNasdaqRedwood City, CA

Corcept Therapeutics

Corcept Therapeutics develops selective cortisol modulators and glucocorticoid receptor antagonists.

SEC EDGAR ClinicalTrials.gov corcept.com

8-KSep 23Latest SEC filing, period to Sep 22

Sep 30Latest story

September 2026

Corcept's miricorilant MASLD Phase 1 study completed, University of Missouri site

Sep 30Trial updateCorcept Therapeutics miricorilant

Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancer

Sep 25Trial updateCorcept Therapeutics paclitaxel

Corcept names Justin Gunn to succeed retiring endocrinology president Sean Maduck

Sep 23PeopleCorcept Therapeutics

July 2026

Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarter

Jul 29Quarterly updateCorcept Therapeutics mifepristone